Company profile: Cormorant Pharma
1.1 - Company Overview
Company description
- Provider of biopharmaceutical research and development focused on IL-8's role in malignant tumors, including the HuMax-IL8 program acquired from Genmab A/S. The privately held company is based at the Karolinska Institute Science Park in Stockholm, Sweden.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Cormorant Pharma
Aimmune Therapeutics
HQ: United States
Website
- Description: Provider of characterized oral desensitization immunotherapy for food allergies, including PALFORZIA to reduce the frequency and severity of reactions to accidental peanut exposure. Develops investigational therapies for food, gastrointestinal, and metabolic-related diseases, conducts human clinical trials to support marketing applications to regulatory authorities, and offers an expanded access policy compliant with FDA regulations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aimmune Therapeutics company profile →
4-Antibody
HQ: Switzerland
Website
- Description: Provider of a human antibody drug-discovery platform focused on immuno-oncology, leveraging Retrocyte Display to generate therapeutic antibody candidates from human libraries expressed in mammalian B-lineage lymphocytes, and developer of a pipeline including Botensilimab (CTLA-4), Balstilimab (PD-1), Zalifrelimab (CTLA-4), AGEN2373 (anti-CD137), AGEN1571 (ILT-2) and ILT4 antagonists, with ongoing clinical trials across multiple cancers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full 4-Antibody company profile →
Theravectys
HQ: France
Website
- Description: Provider of a proprietary lentiviral vector platform for developing vaccines and immunotherapies to prevent and treat infectious diseases, cancers, and other conditions. Pipeline includes Lenti-HPV-07 (Phase 1) for HPV16/18-induced oropharyngeal and cervical cancers, Lenti-COVID intranasal vaccine for SARS-CoV-2 variants, and LV-DEN tetravalent T-cell dengue vaccine. Initial clinical focus includes HIV/AIDS.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Theravectys company profile →
Baliopharm
HQ: Germany
Website
- Description: Provider of novel therapeutics developing monoclonal and bispecific antibodies for autoimmune diseases, chronic liver diseases such as NASH, B-cell malignancies, and cancer. Products include Atrosab and Atrosimab, TNF-R1 targeting antibodies for liver and immune-mediated inflammatory diseases, and Novotarg, a CD20/CD95-targeting bispecific for autoimmune diseases and B-cell malignancies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Baliopharm company profile →
Lyell
HQ: United States
Website
- Description: Provider of cellular immunotherapies and T-cell reprogramming for solid tumors, including CAR T-cell and TIL therapies. Offerings include Epi-R to generate stem-like T cells, Stim-R to optimize delivery of immune-activating molecules, and Rejuvenation Technology to reduce epigenetic age and enhance proliferation and antitumor activity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lyell company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Cormorant Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Cormorant Pharma
2.2 - Growth funds investing in similar companies to Cormorant Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Cormorant Pharma
4.2 - Public trading comparable groups for Cormorant Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →